AMLX
Price
$6.58
Change
+$0.16 (+2.50%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
571.84M
35 days until earnings call
REGN
Price
$547.74
Change
+$22.74 (+4.33%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
59.14B
29 days until earnings call
Interact to see
Advertisement

AMLX vs REGN

Header iconAMLX vs REGN Comparison
Open Charts AMLX vs REGNBanner chart's image
Amylyx Pharmaceuticals
Price$6.58
Change+$0.16 (+2.50%)
Volume$63.46K
Capitalization571.84M
Regeneron Pharmaceuticals
Price$547.74
Change+$22.74 (+4.33%)
Volume$11.72K
Capitalization59.14B
AMLX vs REGN Comparison Chart in %
Loading...
AMLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMLX vs. REGN commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and REGN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (AMLX: $6.57 vs. REGN: $547.74)
Brand notoriety: AMLX: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 188% vs. REGN: 59%
Market capitalization -- AMLX: $571.84M vs. REGN: $59.14B
AMLX [@Biotechnology] is valued at $571.84M. REGN’s [@Biotechnology] market capitalization is $59.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, AMLX is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • AMLX’s TA Score: 4 bullish, 4 bearish.
  • REGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AMLX is a better buy in the short-term than REGN.

Price Growth

AMLX (@Biotechnology) experienced а +2.57% price change this week, while REGN (@Biotechnology) price change was +5.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +33.16%, and the average quarterly price growth was +1.56%.

Reported Earning Dates

AMLX is expected to report earnings on Aug 07, 2025.

REGN is expected to report earnings on Aug 01, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($59.1B) has a higher market cap than AMLX($572M). REGN has higher P/E ratio than AMLX: REGN (13.60) vs AMLX (2.69). AMLX YTD gains are higher at: 73.942 vs. REGN (-22.893). REGN has higher annual earnings (EBITDA): 5.53B vs. AMLX (-206.81M). REGN has more cash in the bank: 8.35B vs. AMLX (204M). AMLX has less debt than REGN: AMLX (1.38M) vs REGN (2.71B). REGN has higher revenues than AMLX: REGN (14.1B) vs AMLX (-1.27M).
AMLXREGNAMLX / REGN
Capitalization572M59.1B1%
EBITDA-206.81M5.53B-4%
Gain YTD73.942-22.893-323%
P/E Ratio2.6913.6020%
Revenue-1.27M14.1B-0%
Total Cash204M8.35B2%
Total Debt1.38M2.71B0%
FUNDAMENTALS RATINGS
REGN: Fundamental Ratings
REGN
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
53
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXREGN
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
54%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
60%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 16 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XBI84.791.71
+2.06%
SPDR® S&P Biotech ETF
BKMC103.580.70
+0.68%
BNY Mellon US Mid Cap Core Equity ETF
TDSC24.460.11
+0.45%
ETC Cabana Target Drawdown 10 ETF
DMAX25.820.02
+0.09%
iShares Large Cap Max Buffer Dec ETF
CARZ61.95N/A
N/A
First Trust S-Network Fut Vhcl&Tech ETF

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been closely correlated with XOMAO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if AMLX jumps, then XOMAO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
+2.57%
XOMAO - AMLX
68%
Closely correlated
+0.55%
XOMAP - AMLX
51%
Loosely correlated
+0.12%
RGNX - AMLX
46%
Loosely correlated
+4.74%
OCUL - AMLX
45%
Loosely correlated
+3.96%
JAZZ - AMLX
43%
Loosely correlated
+0.44%
More